Skip to Content
Merck
All Photos(1)

Documents

SML3925

Sigma-Aldrich

Liraglutide

≥95% (HPLC)

Synonym(s):

Arg34, Lys26-[Nε(γ-Glu[Nα-hexadecanoyl])]-GLP-1[7-37], H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-Lys-α-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, HAEGTFTSDVSSYLEGQAA-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]K-EFIAWLVRGRG, NN2211

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C172H265N43O51
CAS Number:
204656-20-2
Molecular Weight:
3751.20
UNSPSC Code:
51111800
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

color

white to off-white

storage temp.

-10 to -25°C

Biochem/physiol Actions

Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1)-based incretin mimetic (cAMP stimulation EC50 = 61 nM vs 55 nM with GLP-1(7-37) using human GLP-1 receptor-expressing BHK cells), where GLP-1(7-37) sequence is modified with a Lys34-to-Arg substitution and a γ-Glu-C16 acylation on Lys26 for enhanced in vivo stability (plasma t1/2 in pigs post s.c. = 14 h vs 1.2 h with GLP-1(7-37)) and efficacy against type 2 diabetes and obesity (400 μg/kg/day s.c. in rats; 100-200 μg/kg bid or single 50-200 μg/kg i.v. in rats; 100 μg/kg bid or single 30-1000 μg/kg s.c. in mice; 2 μg/kg i.v. or 3.3 μg/kg/day s.c. in pigs).

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361d

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

29953740
Basic and Clinical Pharmacology and Toxicology, 123(6), 704-713 (2018)
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs
European Journal of Pharmacology, 451(2), 217-225 (2002)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
Journal of Medicinal Chemistry, 43(9), 1664-1669 (2000)
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats
Diabetes, 50(11), 2530-2539 (2001)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice
American Journal of Physiology. Endocrinology and Metabolism, 283(4), E745-E752 (2002)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service